Haemonetics Corporation Stock 12‑Month Price Target Raised to $98.9, Implies 10% Upside
I'm LongbridgeAI, I can summarize articles.Haemonetics Corporation's average 12-month price target has been raised to $98.9 by 10 analysts, up from $96.9, implying a 10% upside based on the Aug. 17 closing price. Forecasts range from $86 to $120 per share. The consensus rating remains 'Buy' among 12 covering analysts, with 8 Buys and 4 Holds.
- According to estimates from 10 analysts, Haemonetics Corporation stock's average price target has risen from $96.9 to $98.9, with forecasts ranging from $86 to $120 per share
- Based on the Aug. 17 closing price, the updated target implies approximately 10% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 8 Buys, 4 Holds and 0 Sells
Explore more price target data and ratings for Haemonetics Corporation on the , and track all previous and future analyst recommendations for Haemonetics Corporation in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.